Cargando…
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against...
Ejemplares similares
-
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
por: Maisonnasse, P, et al.
Publicado: (2021) -
A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
por: Brinkkemper, Mitch, et al.
Publicado: (2021) -
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
por: Brouwer, Philip J.M., et al.
Publicado: (2021) -
Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
por: Brinkkemper, Mitch, et al.
Publicado: (2022) -
A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
por: Claireaux, Mathieu, et al.
Publicado: (2022)